Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Aeras
Street 1: 1405 Research Boulevard
Street 2:
City: Rockville
Province: Maryland
Post Code: 20850
Country: United States of America
Phone: 3015472900
Web Site:

Focal Point Contact Information

Salutation: Ms
First Name: Jennifer
Last Name: Woolley
Title: Consultant

Alternate Focal Point Contact Information

Salutation: Dr.
First Name: Lewis
Last Name: Schrager
Title: Vice President, Scientific Affairs

General Information

Board Constituency: Developed Country NGO
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Is your organization legally registered in your country: Yes
Organization Reach: International
Organization Description:
eras is a nonprofit biotech advancing the development of tuberculosis vaccines for the world. In collaboration with global partners in Africa, Asia, North America and Europe, Aeras is supporting the clinical testing of six experimental vaccines as well as a robust portfolio of earlier stage candidates. Aeras receives funding from Australian AID, the Bill & Melinda Gates Foundation, the UK Department for International Development, the Netherlands’ Ministry of Foreign Affairs, and a range of other governments. Aeras is based in Rockville, Maryland; Cape Town, South Africa; and Beijing, China
Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 100 +
Number of part-time staff who are directly involved with TB: 0
Number of volunteers who are directly involved with TB: 0
What is your organization's annual budget (USD) dedicated to TB? >$10 MIL
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
Are you a member of a Stop TB national partnership: United States of America
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Aeras is focused on the development of new, more effective TB vaccines. New vaccines could have a significant impact on the TB epidemic; in fact, eliminating TB will not be possible without more effective vaccines.

Geographical Reach

Which country is your headquarters located in: United States of America
Which WHO region is the main focus of your work: Global
Which countries do you do operate in:
(This includes countries you are conducting activities in)
South Africa
United States of America


Funding, including innovative and optimized approach to funding TB Care
Research and Development

Specializations in Countries

Research and Development China
Research and Development Kenya
Research and Development South Africa
Research and Development United States of America
Research and Development Zambia


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
Aeras collaborates with the TB advocacy community to help raise awareness of TB as a global health issue and to raise the profile of the importance of research, and particularly TB vaccine R&D, to global, regional and national efforts to eliminate TB.

New TB Vaccines:
Aeras is a fully integrated, global nonprofit biotech with capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field Aeras has sponsored and conducted over 25 clinical vaccine trials enrolling thousands of subjects, and is a key partner in six active clinical development programs.


Declaration of interests:
No conflicts of interest were delacred.

Application date:  
Last updated: June 17, 2014